On Friday, in the course of current trade, Shares of The Coca-Cola Company (NYSE:KO), dropped -0.31%, and is now trading at $39.98.
In 1986, Sprite became one of the first mainstream brands to acknowledge the cultural impact of hip-hop by creating a pioneering national television commercial featuring rapper Kurtis Blow. Nearly 30 years later, Sprite continues to evolve its role in hip-hop with the launch of 16 limited-edition package designs that pay homage to some of the most admired lyricists of all time.
The first edition of the Sprite “Obey your Verse” Lyrical Collection features inspirational lyrics from rap superstars Drake, Nas, The Notorious B.I.G. and Rakim. The artists were selected based on their reputation for being true to themselves through their music and advancing the culture. Each artist’s lyrics will appear on individual 12- and 16-ounce cans, 20-ounce bottles, and 12-, 20- and 24-packs of 12-ounce cans, which are accessible now in stores nationwide through the end of summer.
“Sprite recognized and respected the power of hip-hop early, and it became a part of the brand’s essence decades ago,” said Kimberly Paige, Vice President, Sprite Brands and Flavors, Coca-Cola North America. “By honoring and recognizing great lyricism from some of the genre’s biggest icons on our product packaging, we’re demonstrating how Sprite continues to support hip-hop artists that remain true to themselves.”
The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages comprise nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters.
During an early morning trade, Shares of MetLife, Inc. (NYSE:MET), dipped -0.21%, and is now trading at $55.95.
MetLife Foundation declared a three-year partnership with Rockefeller Philanthropy Advisors (RPA) and Bankable Frontier Associates, LLC (BFA) to develop Optimizing Performance Through Improved Cross(X)-Sell (OPTIX), a program to provide microfinance institutions and cooperatives with a breadth of financial tools that can assist them to better serve their clients.
The microfinance institutions and cooperatives comprise: Cooperativa Acreimex in Mexico, Banco WWB in Colombia, SAJIDA Foundation in Bangladesh and Capital Aid Fund for Employment of the Poor (CEP) in Vietnam. OPTIX will assist these four “socially-driven” financial service providers build and strengthen a full suite of financial offerings for their low-income clients. Cross-selling a variety of financial products may ensure client retention, secure their niche against larger competitors and allow them to meet the particular needs of the market segments they serve.
Low-income households in the developing world face a triple-threat when managing their financial well-being. Their incomes are not only low but also irregular and unpredictable. Because of this they need to manage their cash flows more actively than better-off households. In this situation, underserved households generally require a broad array of financial tools. BFA, in partnership with RPA, will build a set of tools to effectively assist institutions’ planned and tactical thinking about how to improve cross-sell through a three step process:
- Design analytical frameworks to test and define opportunities to enhance cross-sell
- Develop the cross-sell strategy using client insights
- Implement, monitor and reevaluate the cross-sell strategy
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding.
Finally, Opko Health, Inc. (NYSE:OPK), lost -0.63% Friday.
OPKO Health, declared that the company will present new data on its long-acting clotting Factor VIIa-CTP (MOD-5014) at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress being held June 20-25, 2015 in Toronto, Ontario, Canada. OPKO’s Factor VIIa-CTP is a next-generation investigational therapy presently in a Phase 2a U.S. based study for the treatment of patients with hemophilia.
Presently, Factor VIIa therapy is accessible only as an intravenous (IV) formulation, which requires frequent multiple infusions to treat a bleeding episode due to Factor VIIa’s short half-life. In addition, the requirement for multiple weekly infusions can be onerous for patients interested in preventative prophylactic treatment of the disease, especially children.
Formerly presented pre-clinical data utilizing both intravenous and subcutaneous administration in hemophilic animal models demonstrated the long acting properties of Factor VIIa-CTP as contrast to commercial rFVIIa, with superior half-life, reduced bleeding and raised survival for a significantly longer period.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
